Search

Your search keyword '"Leypoldt, Lisa B."' showing total 21 results
Start Over Author "Leypoldt, Lisa B."
21 results on '"Leypoldt, Lisa B."'

1. Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial

Author

Mai, Elias K., Bertsch, Uta, Pozek, Ema, Fenk, Roland, Besemer, Britta, Hanoun, Christine, Schroers, Roland, von Metzler, Ivana, Hänel, Mathias, Mann, Christoph, Leypoldt, Lisa B., Heilmeier, Bernhard, Huhn, Stefanie, Vogel, Sabine K., Hundemer, Michael, Scheid, Christof, Blau, Igor W., Luntz, Steffen, Weinhold, Niels, Tichy, Diana, Holderried, Tobias A.W., Trautmann-Grill, Karolin, Gezer, Deniz, Klaiber-Hakimi, Maika, Müller, Martin, Shumilov, Evgenii, Knauf, Wolfgang, Michel, Christian S., Geer, Thomas, Riesenberg, Hendrik, Lutz, Christoph, Raab, Marc S., Benner, Axel, Hoffmann, Martin, Weisel, Katja C., Salwender, Hans J., Goldschmidt, Hartmut, Ahlborn, Miriam, Behringer, Joachim, Bernhard, Helga, Besemer, Britta, Bittenbring, Jörg, Blau, Igor Wolfgang, Bolling, Claus, Boquoi, Amelie, Debatin, Daniel, Egerer, Gerlinde, Fenk, Roland, Ferstl, Barbara, Fronhoffs, Stefan, Gaska, Tobias, Geer, Thomas, Gezer, Deniz, Goldschmidt, Hartmut, Görner, Martin, Graeven, Ullrich, Hänel, Mathias, Heilmeier, Bernhard, Heinsch, Michael, Hoffmann, Martin, Holderried, Tobias A.W., Hopfer, Olaf, Janjetovic, Snjezana, Klaiber-Hakimi, Maika, Klausmann, Martine, Klein, Stefan, Knauf, Wolfgang, Ko, Yon-Dschun, Kraemer, Doris Maria, Kropff, Martin, La Rosée, Paul, Mahlberg, Rolf, Mann, Christoph, Martens, Uwe, von Metzler, Ivana, Michel, Christian, Müller, Martin, Pönisch, Wolfram, Reimer, Peter, Riechel, Claudia, Ringhoffer, Mark, Rummel, Mathias, Runde, Volker, Salwender, Hans Jürgen, Schaich, Markus, Scheid, Christoph, Schmidt-Hieber, Martin, Schöndube, Daniel, Schroers, Roland, Schütte, Hans-Joachim, Shumilov, Evgenii, Staib, Peter, Strumberg, Dirk, Tischler, Hans-Joachim, Trautmann-Grill, Karolin, Verbeek, Walter, Weide, Rudolf, Weidmann, Eckhart, Weisel, Katja, de Wit, Maike, Bernhardt, Christiane, Fietz, Thomas, Grassinger, Jochen, Köchling, Georg, Neise, Michael, Schmitt, Stefan, Steiniger, Heike, Tschechne, Barbara, Whitlock, Bettina, Zaiß, Matthias, and Ziske, Carsten

Published
2024
Full Text
View/download PDF

3. Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma.

Author

Leypoldt, Lisa B., Tichy, Diana, Besemer, Britta, Hanel, Mathias, Raab, Marc S., Mann, Christoph, Munder, Markus, Reinhardt, Hans Christian, Nogai, Axel, Gorner, Martin, Ko, Yon-Dschun, de Wit, Maike, Salwender, Hans, Scheid, Christof, Graeven, Ullrich, Peceny, Rudolf, Staib, Peter, Dieing, Annette, Einsele, Hermann, and Jauch, Anna

Abstract

Plain Language Summary What is this summary about? This is a summary of a publication about the GMMG-CONCEPT study that was published in the Journal of Clinical Oncology in September 2023. The study tested if a combination of cancer drugs (isatuximab plus carfilzomib, lenalidomide, and dexamethasone, or Isa-KRd for short) was a safe treatment for people with high-risk newly diagnosed multiple myeloma. The GMMG-CONCEPT study included participants who had not been treated before and were eligible to receive a procedure called autologous stem cell transplant, as well as participants who were not eligible to receive transplants. How was the study in this summary conducted? This report looked at a total of 125 participants; 99 were transplant-eligible and 26 were transplant-non-eligible. All participants were treated with Isa-KRd. The researchers measured the proportion of people who had 'no detectable levels' of myeloma cells in their body left while on treatment (called minimal residual disease negativity, or MRD negativity for short). The researchers measured the progression-free survival, or the average length of time it took between the participants joining the study until their cancer got worse or they died. The researchers also measured overall survival, which is the total amount of time people lived during the study, even if their cancer got worse. The researchers also monitored for side effects of Isa-KRd in all participants that received at least one treatment. What were the results of the study? At the end of the consolidation therapy (intensified therapy that happens after initial therapy), MRD negativity was observed in the majority of transplant-eligible and transplant non-eligible patients. For many patients, this effect lasted 6 or more months. After more than 3 years in transplant eligible participants and 2 years and 9 months for transplant non-eligible participants, most participants were alive and their disease did not get worse. In both groups, the most common side effects of Isa-KRd treatment were low blood cell counts and infections. Overall, most of the side effects did not last long or were easily treated. What were the main conclusions reported by the researchers? In the GMMG-CONCEPT study, Isa-KRd treatment reduced the number of myeloma cells to no detectable levels in more than two thirds of the participants with high-risk newly diagnosed multiple myeloma. Clinical Trial Registration:NCT03104842 (ClinicalTrials.gov) [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial

Author

Leypoldt, Lisa B., Besemer, Britta, Asemissen, Anne Marie, Hänel, Mathias, Blau, Igor Wolfgang, Görner, Martin, Ko, Yon-Dschun, Reinhardt, Hans Christian, Staib, Peter, Mann, Christoph, Lutz, Raphael, Munder, Markus, Graeven, Ullrich, Peceny, Rudolf, Salwender, Hans, Jauch, Anna, Zago, Manola, Benner, Axel, Tichy, Diana, Bokemeyer, Carsten, Goldschmidt, Hartmut, and Weisel, Katja C.

Published
2022
Full Text
View/download PDF

6. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

Author

Leypoldt, Lisa B., primary, Tichy, Diana, additional, Besemer, Britta, additional, Hänel, Mathias, additional, Raab, Marc S., additional, Mann, Christoph, additional, Munder, Markus, additional, Reinhardt, Hans Christian, additional, Nogai, Axel, additional, Görner, Martin, additional, Ko, Yon-Dschun, additional, de Wit, Maike, additional, Salwender, Hans, additional, Scheid, Christof, additional, Graeven, Ullrich, additional, Peceny, Rudolf, additional, Staib, Peter, additional, Dieing, Annette, additional, Einsele, Hermann, additional, Jauch, Anna, additional, Hundemer, Michael, additional, Zago, Manola, additional, Požek, Ema, additional, Benner, Axel, additional, Bokemeyer, Carsten, additional, Goldschmidt, Hartmut, additional, and Weisel, Katja C., additional

Published
2023
Full Text
View/download PDF

7. Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial

Author

Leypoldt, Lisa B., primary, Gavriatopoulou, Maria, additional, Besemer, Britta, additional, Salwender, Hans, additional, Raab, Marc S., additional, Nogai, Axel, additional, Khandanpour, Cyrus, additional, Runde, Volker, additional, Jauch, Anna, additional, Zago, Manola, additional, Martus, Peter, additional, Goldschmidt, Hartmut, additional, Bokemeyer, Carsten, additional, Dimopoulos, Meletios A., additional, and Weisel, Katja C., additional

Published
2023
Full Text
View/download PDF

8. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.

Author

Leypoldt, Lisa B., Tichy, Diana, Besemer, Britta, Hänel, Mathias, Raab, Marc S., Mann, Christoph, Munder, Markus, Reinhardt, Hans Christian, Nogai, Axel, Görner, Martin, Ko, Yon-Dschun, de Wit, Maike, Salwender, Hans, Scheid, Christof, Graeven, Ullrich, Peceny, Rudolf, Staib, Peter, Dieing, Annette, Einsele, Hermann, and Jauch, Anna

Published
2024
Full Text
View/download PDF

10. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma: Planned Interim Analysis of the GMMG-Concept Trial

Author

Weisel, Katja, primary, Besemer, Britta, additional, Haenel, Mathias, additional, Lutz, Raphael, additional, Mann, Christoph, additional, Munder, Markus, additional, Goerner, Martin, additional, Reinhardt, Hans Christian, additional, Nogai, Axel, additional, Ko, Yon-Dschun, additional, De Wit, Maike, additional, Salwender, Hans, additional, Scheid, Christoph, additional, Graeven, Ullrich, additional, Peceny, Rudolf, additional, Staib, Peter, additional, Dieing, Annette, additional, Jauch, Anna, additional, Zago, Manola, additional, Benner, Axel, additional, Tichy, Diana, additional, Bokemeyer, Carsten, additional, Goldschmidt, Hartmut, additional, and Leypoldt, Lisa B., additional

Published
2022
Full Text
View/download PDF

11. Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study

Author

Schönlein, Martin, Wrage, Victoria, Ghandili, Susanne, Mellinghoff, Sibylle C., Brehm, Thomas Theo, Leypoldt, Lisa B., Utz, Nils, Schrader, Roland M., Alsdorf, Winfried, Börschel, Niklas, Bußmann, Lara, Schönrock, Martin, Perlick, Dorothea, Schön, Gerhard, Verpoort, Karl, Lütgehetmann, Marc, Schulze zur Wiesch, Julian, Weisel, Katja C., Bokemeyer, Carsten, Schafhausen, Philippe, and Sinn, Marianne

Published
2022
Full Text
View/download PDF

12. Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients-COVIDOUT study

Author

Schoenlein, Martin, Wrage, Victoria, Ghandili, Susanne, Mellinghoff, Sibylle C., Brehm, Thomas Theo, Leypoldt, Lisa B., Utz, Nils, Schrader, Roland M., Alsdorf, Winfried, Boerschel, Niklas, Bussmann, Lara, Schoenrock, Martin, Perlick, Dorothea, Schoen, Gerhard, Verpoort, Karl, Luetgehetmann, Marc, zur Wiesch, Julian Schulze, Weisel, Katja C., Bokemeyer, Carsten, Schafhausen, Philippe, Sinn, Marianne, Schoenlein, Martin, Wrage, Victoria, Ghandili, Susanne, Mellinghoff, Sibylle C., Brehm, Thomas Theo, Leypoldt, Lisa B., Utz, Nils, Schrader, Roland M., Alsdorf, Winfried, Boerschel, Niklas, Bussmann, Lara, Schoenrock, Martin, Perlick, Dorothea, Schoen, Gerhard, Verpoort, Karl, Luetgehetmann, Marc, zur Wiesch, Julian Schulze, Weisel, Katja C., Bokemeyer, Carsten, Schafhausen, Philippe, and Sinn, Marianne

Published
2022

13. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma: Planned Interim Analysis of the GMMG-Concept Trial

Author

Weisel, Katja, Besemer, Britta, Haenel, Mathias, Lutz, Raphael, Mann, Christoph, Munder, Markus, Goerner, Martin, Reinhardt, Hans Christian, Nogai, Axel, Ko, Yon-Dschun, De Wit, Maike, Salwender, Hans, Scheid, Christoph, Graeven, Ullrich, Peceny, Rudolf, Staib, Peter, Dieing, Annette, Jauch, Anna, Zago, Manola, Benner, Axel, Tichy, Diana, Bokemeyer, Carsten, Goldschmidt, Hartmut, Leypoldt, Lisa B., Weisel, Katja, Besemer, Britta, Haenel, Mathias, Lutz, Raphael, Mann, Christoph, Munder, Markus, Goerner, Martin, Reinhardt, Hans Christian, Nogai, Axel, Ko, Yon-Dschun, De Wit, Maike, Salwender, Hans, Scheid, Christoph, Graeven, Ullrich, Peceny, Rudolf, Staib, Peter, Dieing, Annette, Jauch, Anna, Zago, Manola, Benner, Axel, Tichy, Diana, Bokemeyer, Carsten, Goldschmidt, Hartmut, and Leypoldt, Lisa B.

Published
2022

14. Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma

Author

Ghandili, Susanne, primary, Schönlein, Martin, additional, Wiessner, Christian, additional, Becher, Heiko, additional, Lütgehetmann, Marc, additional, Brehm, Thomas Theo, additional, Schulze zur Wiesch, Julian, additional, Bokemeyer, Carsten, additional, Sinn, Marianne, additional, Weisel, Katja C., additional, and Leypoldt, Lisa B., additional

Published
2021
Full Text
View/download PDF

15. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial

Author

Leypoldt, Lisa B., primary, Besemer, Britta, additional, Asemissen, Anne Marie, additional, Hänel, Mathias, additional, Blau, Igor Wolfgang, additional, Görner, Martin, additional, Ko, Yon-Dschun, additional, Reinhardt, Hans Christian, additional, Staib, Peter, additional, Mann, Christoph, additional, Lutz, Raphael, additional, Munder, Markus, additional, Graeven, Ullrich, additional, Peceny, Rudolf, additional, Salwender, Hans, additional, Jauch, Anna, additional, Zago, Manola, additional, Benner, Axel, additional, Tichy, Diana, additional, Bokemeyer, Carsten, additional, Goldschmidt, Hartmut, additional, and Weisel, Katja C., additional

Published
2021
Full Text
View/download PDF

16. Targeting Mutant KRAS with Novel Mutant-Specific Pharmacological Inhibitors: Activity Against Myeloma and Other Lymphoid Malignant Cells and Molecular Mechanisms of Resistance

Author

Steinbrunn, Torsten, Shirasaki, Ryosuke, Dashevsky, Olga, Tang, Huihui, Yamano, Shizuka, Mizuno, Rin, Sugihara, Takeru, Teoh, Phaik Ju, Leypoldt, Lisa B, Kaji, Mariko, Sorrell, Jeffrey, Glassner, Brian J, De Matos Simoes, Ricardo, Christensen, James, and Mitsiades, Constantine S

Published
2023
Full Text
View/download PDF

20. Depth of Response to Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (Isa-KRd) in Front-Line Treatment of High-Risk Multiple Myeloma: Interim Analysis of the GMMG-CONCEPT Trial

Author

Leypoldt, Lisa B., primary, Asemissen, Anne Marie, additional, Besemer, Britta, additional, Haenel, Mathias, additional, Blau, Igor Wolfgang, additional, Görner, Martin, additional, Ko, Yon-Dschun, additional, Reinhardt, Hans Christian, additional, Staib, Peter, additional, Mann, Christoph, additional, Lutz, Raphael, additional, Munder, Markus, additional, Graeven, Ullrich, additional, Peceny, Rudolf, additional, Salwender, Hans, additional, Jauch, Anna, additional, Zago, Manola, additional, Benner, Axel, additional, Tichy, Diana, additional, Bokemeyer, Carsten, additional, Goldschmidt, Hartmut, additional, Weisel, Katja C., additional, and Group (GMMG), German Speaking Myeloma Multicenter, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results